New CAR t therapy targets tough leukemia in early trial

NCT ID NCT06326021

Recruiting now Disease control Sponsor: Beijing GoBroad Hospital Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 31 times

Summary

This early-phase trial tests a new treatment called FL-33 CAR T for people with acute myeloid leukemia (AML) that has come back or not responded to standard therapy. The treatment uses a patient's own immune cells, modified to find and attack cancer cells with a specific marker (CD33). The main goals are to check safety and find the best dose, with up to 27 participants aged 1 to 70.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for REFRACTORY/RELAPSED ACUTE MYELOID LEUKAEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

BeijingGoBroadH
RECRUITING

Beijing, China

Contact Phone: •••-•••-•••• Email: •••••@•••••
Shanghai Liquan Hospital
NOT_YET_RECRUITING

Shanghai, Shanghai Municipality, 201418, China
The General Hospital of Western Theater Command PLA
NOT_YET_RECRUITING

Chengdu, Sichuan, 610083, China
Zhaxin Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai
NOT_YET_RECRUITING

Shanghai, Shanghai Municipality, 200435, China

Conditions

Explore the condition pages connected to this study.

REFRACTORY/RELAPSED ACUTE MYELOID LEUKAEMIA REFRACTORY/RELAPSED ACUTE MYELOID LEUKAEMIA